The application leverages existing clinical data for Uzedy along with prior FDA findings on the safety of Udezy in patients ...

Parsippany, New Jersey Thursday, February 27, 2025, 13:00 Hrs [IST] ...

We recently compiled a list of the 12 Best Low Price Pharma Stocks To Invest In Right Now. In this article, we are going to ...

Teva Pharmaceuticals (TEVA) and Medincell (MEDCL) announced that the supplemental New Drug Application sNDA for UZEDY extended-release ...

Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries, and Medincell announced that the supplemental New Drug ...

Israel-headquartered Teva Pharmaceutical Industries’ US subsidiary and France’s and Medincell announced that the supplemental ...

The company credited much of that growth to higher generic sales around the world plus the continued strength of branded drugs Austedo, Uzedy and Ajovy. As for 2025, Teva expects to generate sales ...

There was a lot to like in Teva's Q4 report, notably: AUSTEDO and UZEDY had strong years, growing at 34% and 18% to $1.6B and $117M respectively. It should be noted that comparisons to Q4 2023 ...

Huntington's treatment Austedo and its schizophrenia drug Uzedy. Teva forecast 2025 revenue of $16.8 billion to $17.4 billion and diluted EPS ex-one offs of $2.35-$2.65. Analysts expect revenue of ...

TEVA), and Medincell (Euronext: MEDCL), announced today that the supplemental New Drug Application (sNDA) for UZEDY extended-release injectable suspension for the maintenance treatment of BP-I in ...

The FDA has accepted a supplemental New Drug Application submitted by Teva (NYSE:TEVA) and Medincell (OTC:MDCLF) for Uzedy ...

UZEDY is currently approved for use every one or two months as a subcutaneous long-acting injectable (LAI) for the treatment ...